TRPC6抗体;TRPC6 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11395(TRPC6 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11395(TRPC6 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

TRPC6 (Transient Receptor Potential Canonical 6) is a calcium-permeable non-selective cation channel belonging to the TRP superfamily. It is widely expressed in tissues such as the kidneys, cardiovascular system, and nervous system. TRPC6 is activated by diacylglycerol (DAG) and mechanical stress, playing critical roles in regulating cellular calcium signaling, which influences processes like cell proliferation, apoptosis, and gene expression. Dysregulation of TRPC6 has been linked to various pathologies, including kidney diseases (e.g., focal segmental glomerulosclerosis, FSGS), cardiovascular disorders (e.g., hypertension, cardiac hypertrophy), and neurological conditions.

TRPC6 antibodies are essential tools for studying the channel's expression, localization, and function. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect TRPC6 in experimental models or clinical samples. In research, these antibodies help elucidate TRPC6's role in disease mechanisms, such as its overexpression in podocyte injury or its contribution to abnormal vascular smooth muscle contraction. Additionally, TRPC6-targeting antibodies are explored for therapeutic potential, particularly in blocking pathogenic signaling in renal or cardiovascular diseases. Mutations in the TRPC6 gene, identified in hereditary FSGS, further underscore its clinical relevance. As TRPC6 continues to emerge as a biomarker and drug target, specific antibodies remain vital for both basic research and translational applications.